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ABSTRACT 25 
Targeting of specific receptors on antigen-presenting cells is an appealing prospect in the 26 
production of novel nanoparticulate vaccines. In particular, the targeting of vaccines to 27 
dendritic cell (DC) subsets has been shown in models to significantly improve the induction of 28 
immune responses. This paper describes the evaluation of natural ligands, mannan and 29 
chitosan, and monoclonal antibodies as targeting motifs to enhance uptake of PLGA 30 
nanoparticle carriers by bovine DCs.  To assess enhancement of uptake after the addition of 31 
natural ligands a bovine monocyte derived DC (MoDC) model was used. For the assessment 32 
of monoclonal antibody targeting, the model was expanded to include afferent lymph DCs 33 
(ALDCs) in a competitive uptake assay. Mannan, proved unsuccessful at enhancing uptake or 34 
targeting by MoDCs. Chitosan coated particle uptake could be impeded by the addition of 35 
mannan suggesting uptake may be mediated through sugar receptors. Inclusion of 36 
monoclonal antibodies specific for the DEC-205 (CD205) receptor increased the number of 37 
receptor expressing DCs associated with particles as well as the number of particles taken up 38 
by individual cells.  These results support the further evaluation of active targeting of 39 
nanovaccines to DCs to enhance their immunogenicity in cattle and other large mammalian 40 
species including humans.  41 
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 47 
1. INTRODUCTION 48 
Nanoparticulate delivery of subunit vaccines offers a number of potential advantages 49 
over conventional approaches including preferential uptake by dendritic cells (DC) and 50 
prolonged release of antigen resulting in enhanced T cell stimulation [1]. Furthermore, 51 
nanoparticles offer a versatile system that allows for targeted delivery of antigen and 52 
adjuvant to the same DC [2]. It is generally acknowledged that DCs are capable of taking up 53 
particles with a varied range of physical properties. Studies have shown enhanced DC uptake 54 
of particles in vitro but few have addressed specific targeting and the uptake of particles by 55 
different cell types [3]. A recent study showed liposomes are taken up primarily by CD11c+ 56 
DCs and macrophages in murine lymph nodes, with the latter being more efficient [4]. 57 
Similarly, it was shown that PLGA nanoparticles are more efficiently taken up by macrophages 58 
than DC [5]. Since DCs are the primary target of most vaccines, these data suggest that 59 
particulate systems may need to be further targeted to specific cell types to achieve optimal 60 
induction of immune responses.    61 
 Targeting of vaccines to DCs via specific receptors can be facilitated with the use of 62 
natural receptor ligands or mAbs specific for DC receptors. Targeting mannose receptors 63 
through mannosylation is the most common means of targeting DCs through natural ligands. 64 
Indeed protein mannosylation has proved effective at both improving antigen uptake and 65 
adjuvanting immune responses [6]. Mannosylation of particles however has yielded variable 66 
results both in terms of enhancing particle uptake or DC maturation [7-9].  67 
Targeting of particles to a cell type using specific mAbs was first evaluated in the 68 
context of cancer drug delivery [10, 11]. Employing the same principle, nanoparticles targeted 69 
to DC using DC-SIGN-specific mAbs generated 10-100 fold increases in the efficiency of 70 
4 
 
antigen-presentation compared to non-targeted particles [12]. mAb targeting of 71 
microparticles to DEC-205 resulted in a two-fold enhancement of immune responses [13]. A 72 
second study targeting nanoparticles using DEC-205 specific mAb reported only a 15% 73 
increase in uptake over particles coated with an irrelevant isotype matched mAb when 74 
targeting immature DCs but a 70% increase when targeting mature DCs [14]. Furthermore, 75 
the properties of different particle types such as their size can affect which DC subset 76 
becomes associated with the particle and thus the type of immune response evoked [15, 16]. 77 
Dendritic cell targeting of biomaterials has been comprehensively reviewed in [17].      78 
 Cattle represent an important veterinary species susceptible to a number of infectious 79 
diseases for which there is a need to develop new or improved vaccines to support control 80 
programmes. Bovine DC subsets have been characterised suggesting that they represent 81 
orthologous populations to those described in humans [18, 19]. As such, cattle provide a large 82 
mammal model species for the evaluation of DC-targeted nanovaccines, which may be useful 83 
in cattle, other animals and humans. As a first step to using the bovine system for the 84 
development of novel nanoparticle vaccine systems, this study describes the synthesis of 85 
targeted PLGA nanoparticles using both natural ligands and mAb and an evaluation of their 86 
effects on uptake by bovine DC in vitro.                                          87 
2. MATERIALS & METHODS 88 
2.1. Isolation of bovine monocytes 89 
All animal work was approved by the APHA Ethics Committee and conducted in accordance 90 
with the UK Animals (Scientific Procedures) Act 1986. Peripheral blood mononuclear cells 91 
(PBMC) were isolated from heparinised blood collected from adult male Holstein-Friesian 92 
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cattle [20]. Monocytes were purified from PBMC by magnetic activated cell sorting (MACS), 93 
using anti-human CD14-microbeads as described by the manufacturer (Miltenyi Biotec).  94 
 95 
2.2. Generation of monocyte derived dendritic cell (MoDC)  96 
Monocytes were resuspended in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml 97 
penicillin and 100 μg/ml streptomycin (cRPMI) and plated at 2x106 cells/well in 24 well Ultra-98 
Low Attachment Tissue Culture Plates (Costar). Differentiation to MoDCs was induced by the 99 
addition of recombinant bovine GM-CSF and IL-4 according to the manufacturer’s 100 
recommended dilution (1:20) (Bovine Dendritic Cell Growth Kit, AbD Serotec, Oxford, UK). 101 
Cells were incubated for 6 days at 37oC in a 5% CO2 humidified atmosphere.  102 
 103 
2.3. Bovine afferent lymph dendritic cells  104 
Cells were collected from afferent lymph following pseudo-afferent lymphatic cannulation 105 
[21] and cryopreserved in 10% (v/v) DMSO in FBS. Cells were thawed rapidly in a 37oC water 106 
bath and washed in pre-warmed cRPMI before use. 107 
 108 
2.4. PLGA nanoparticle synthesis 109 
Acid terminated PLGA (Resomer RG502 H, 50:50, Mw 7-17 kDa, Sigma, Poole, UK) was 110 
dissolved in ethyl acetate (Sigma) at a concentration of 25 mg/ml to form the oil phase (o). 111 
The model antigen ovalbumin (OVA) conjugated Alexa Fluor 488 or Alexa Fluor 647 (Life 112 
Technologies) diluted to 5 mg/ml in DPBS formed the first water phase (w1). 1% (w/v) poly 113 
vinyl alcohol (PVA; 98% hydrolysed Mw 13-23 KDa, Sigma) in distilled water was used as a 114 
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stabilizer in the second water phase (w2). To form the first emulsion (w1/o), w1 was rapidly 115 
added to the oil phase at a ratio of 1:10 and sonicated for 30 sec at an intensity of 14 microns 116 
using a Soniprep 150 sonicator (MSE, London, UK). To form the second emulsion (w1/o/w2), 117 
w1/o was added to w2 at a ratio of 1:5 and sonicated for 2 min at an intensity of 18 microns. 118 
The final emulsion was added to a larger vessel and the solvent was evaporated overnight 119 
with stirring (250 rpm) at 37oC. The particles were collected by ultracentrifugation at 40,000 120 
x g for 20 min and washed twice with distilled water to remove excess PVA. 121 
 122 
2.5. Particle sizing and assessment of surface charge   123 
The hydrodynamic diameter of the particles was calculated using dynamic light scattering 124 
(DLS). Particles were sonicated, dispersed in distilled degassed water and analysed on a 125 
Zetasizer 3000 (Malvern Instruments, Malvern, UK) in a disposable cuvette at 25oC with a 126 
scatter angle of 90o. Eleven readings were made in triplicate. Zeta potential measurements 127 
(20 readings/sample in triplicate) were made using a disposable zeta cell (Malvern 128 
Instruments).        129 
 130 
2.6. Scanning electron microscopy 131 
Particles were air dried onto poly-L-lysine coated coverslips (BD Biosciences, Oxford, UK). 132 
Coverslip were applied to double sided carbon (Agar Scientific, Stansted, UK) attached to a 133 
13mm aluminium stub (Agar Scientific) and sputter coated with gold to a thickness of 15nm 134 
using an Emitech K550X Sputter Coater (Quorum Technologies, Ashford, UK). Particles were 135 
visualized using a Zeiss Evo LS10 scanning electron microscope (Zeiss, Welwyn Garden City, 136 
UK) at an accelerating voltage of 10-20 kV.   137 
 138 
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2.7. Conjugation of mannan and ovalbumin to PLGA nanoparticles 139 
Ligands were conjugated to the surface of PLGA nanoparticles post-synthesis using 1-Ethyl-3-140 
(3-dimethylaminopropyl) carbodiimide (EDC), a carbodiimide cross-linker that activates 141 
carboxyl groups for spontaneous reaction with primary amines as schematically illustrated in 142 
Fig. 2A. Particles were suspended at 10 mg/ml based on the starting amount of PLGA in 0.1M 143 
2-(N-morpholino)ethanesulfonic acid buffer (MES) (Sigma) adjusted to pH 5.2 with 0.1M 144 
hydrochloric acid (HCl). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and sulpho-N-145 
hydroxysuccinimide (Sulpho-NHS) (Sigma) were added at a final concentration of 0.1 M, and 146 
then mannan (MAN) and OVA (Sigma) were added at a final concentration of 5 mg/ml, unless 147 
otherwise indicated. The reaction was carried out overnight with stirring (250 rpm) at room 148 
temperature. Particles were collected by centrifugation at 10,000 x g for 2 min and washed 149 
twice with Tris buffered saline (TBS). To neutralize reactive groups not utilized in the process 150 
and isourea intermediates, particles were resuspended in TBS for 1 hr. The coating of particles 151 
was confirmed by staining with concanavalin A-FITC (ConA-FITC; Sigma) or anti-OVA mAb 152 
(clone OVA-14, Sigma) followed by APC-conjugated anti-mouse IgG1 secondary antibody 153 
(clone X56; BD Biosciences). The particles were washed twice with DPBS and fluorescent 154 
staining assessed using a MACSQuant Analyzer flow cytometer. Particles were gated by 155 
forward (FSC) and side (SSC) scatter measurements (logarithmic scaling); exclusion of 156 
electronic noise was confirmed by running a sample of DPBS. Residual mannose in wash 157 
supernatants was quantified using the colorimetric resorcinol assay as described [22]. In brief 158 
20µl of sample or standard mannan was mixed with an equal volume of 6mg/ml resorcinol in 159 
water and following this 100µl of 75% H2SO4 was added. The reaction was vortexed and 160 
heated to 90oC for 30 min. The reaction was allowed to cool for 30 min before absorbance 161 
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was read at OD450.  Residual OVA in wash supernatants was quantified by measuring 162 
absorbance at OD280. 163 
 164 
    165 
2.8. Chitosan coating of PLGA nanoparticles 166 
PLGA nanoparticles were coated with chitosan by overnight incubation with 1 mg/ml chitosan 167 
salts or chitosan oligomers (all Heppe Medical Chitosan GmbH, Halle, Germany). Unbound 168 
chitosan was removed by washing twice in DPBS. The chitosan molecules assessed included 169 
the salts; carboxy-methyl chitosan and chitosan HCl. The oligomers included sizes ranging 170 
from; <1 KDa, 1-3 KDa, 3-5 KDa and >5 KDa.       171 
 172 
2.9. Monoclonal antibody coating of nanoparticles 173 
To preserve conformation and function, mAb was coated onto PLGA nanoparticles using a 174 
non-crosslinking adherence based method. OVA-Alexa Fluor 647-loaded PLGA nanoparticles 175 
were divided into equal aliquots: 1 mg particles were suspended in 1 ml 0.1 M MES buffer pH 176 
6.2 (Sigma), and either mouse anti-bovine DEC-205 mAb or a relevant isotype control mAb 177 
(both AbD Serotec) were added at a final concentration of 25 µg/ml and incubated overnight 178 
at room temperature. Particles were washed twice with DPBS and coating was confirmed 179 
using FITC conjugated anti-mouse IgG secondary antibody (Sigma) and flow cytometry. 180 
Aliquots of antibody coated particles were further coated with 3-5 kDa oligo chitosan as 181 
described above.         182 
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 183 
2.10. Nanoparticle uptake and inhibition studies 184 
Following 6 days in culture, immature MoDCs were plated at 5x104cells/well in 96-well round-185 
bottom plates (Corning). For the basic uptake assay, PLGA nanoparticles loaded with OVA-186 
Alexa Fluor 488 and matched by polymer weight were added to cells, which were incubated 187 
for 60 min at 37oC or 4oC before washing 3 times (930 x g for 2 minutes) with PBS. For the 188 
inhibition studies, cells were pre-treated with; mannan (MAN; 50 µg/ml), polyinosinic acid 189 
(poly I; 50 µg/ml) or amantidine (50 µg/ml) (all Sigma) for 30 min at 37oC. Uptake was assessed 190 
using a MACSQuant Analyzer flow cytometer. Dead cells were excluded by staining with Near-191 
Infra Red Fixable Live/Dead Cell stain (Life Technologies), and the mean Alexa Fluor 488 192 
fluorescence intensity of viable cells used as a measure of uptake.       193 
 194 
2.11. Afferent lymph dendritic cell / MoDC competitive nanoparticle uptake assay 195 
MoDCs were resuspended in 1 ml PBS with 5% FBS and labelled with carboxyfluorescein 196 
succinimidyl ester (CFSE; Life Technologies) [23]. Afferent lymph cells were analysed using a 197 
volumetric flow cytometer and the density of afferent lymph dendritic cells (ALDC), defined 198 
by a high FSC/SSC profile, was determined. MoDC were mixed with afferent lymph cells at a 199 
ratio that ensured approximately equal numbers of MoDC and ALDC in cRPMI. Cells were 200 
plated at 5x105/wells in a 96 well round-bottom plate and pulsed with particles (25 µg per 201 
well) for 60 min at 37oC. Cells were washed 3 times with cold PBS and stained with Near-Infra 202 
Red Fixable Live/Dead Cell stain (Life Technologies) and a pool of anti-bovine CD80 and CD86 203 
mAbs (clones IL-A159 and IL-A190) conjugated to Alexa Fluor-405 using the Zenon Mouse 204 
IgG1 Labelling Kit (Life Technologies). Analysis was undertaken on a MACSQuant Analyzer flow 205 
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cytometer. DCs were identified as viable cells expressing CD80/86. MoDC and ALDCs were 206 
discriminated on the basis of CFSE fluorescence and particle uptake was assessed as 207 
previously described.          208 
2.12. Statistical analysis 209 
All statistical analysis was performed using GraphPad Prism 5.04 (GraphPad Software Inc., La 210 
Jolla, CA, USA). Two-way analysis of variance (ANOVA) followed by a Bonferroni’s post-test or 211 
unpaired student’s t-tests were used for the analysis where indicated.  A p value <0.05 was 212 
considered statistically significant.  213 
 214 
3. RESULTS 215 
3.1. Characterization of PLGA nanoparticle uptake 216 
PLGA nanoparticle formation was confirmed by scanning electron microscopy (Fig. 1A). 217 
Discrete particles within the nm size range with a smooth surface morphology were observed, 218 
which was confirmed by DLS (Fig. 2I). Furthermore, DLS revealed an acceptable level of poly-219 
dispersity (<0.2). We used flow cytometry to quantify the internalization of PLGA 220 
nanoparticles by bovine MoDC (Fig. 1B). Fluorescent particle uptake was greatly enhanced at 221 
37oC compared to 4oC suggesting an active process was required.  222 
 223 
3.2. Natural ligand targeting of nanoparticles to mannose receptors 224 
This study employed a zero length carbodiimide cross-linker to conjugate MAN or OVA to 225 
PLGA nanoparticles post-synthesis (Fig. 2A). Analysis of the wash supernatants of MAN- and 226 
OVA-coated particles suggested that significant amounts of ligand became bound to the 227 
surface of particles (Fig. 2B and 2C). This was confirmed by staining of particles and analysis 228 
11 
 
by flow cytometry, which showed that ~80% of MAN-coated (Fig. 2D and E) and >90% of OVA-229 
coated (Fig. 2F and G) particles were conjugated. Coating of particles with MAN neutralized 230 
the surface charge however OVA coating had little effect on surface charge (Fig. 2H). MAN 231 
coating slightly increased particle diameter whereas OVA increased it by approximately 50nm 232 
(Fig. 2I).  233 
MoDC uptake of PLGA nanoparticles which were either non-coated or coated with MAN or 234 
OVA was assessed in comparison to soluble OVA using flow cytometry (Fig. 3A). Rather than 235 
enhancing uptake by MoDC, the net uptake of both MAN- and OVA-coated particles when 236 
compared to the non-coated particles was reduced albeit without statistical significance. The 237 
net uptake of all particles was lower than that of the soluble protein. To reveal the 238 
mechanisms involved in MoDC uptake of coated and non-coated PLGA particles, we assessed 239 
particle internalization in the presence of different uptake inhibitors or competing receptor 240 
ligands (Fig. 3B-I). The ability of mannosylated particles to specifically target mannose 241 
receptors was analyzed using soluble MAN as a competitive inhibitor but this had no 242 
inhibitory effect (Fig. 3E and G). Given this unexpected finding, we used flow cytometry and 243 
confirmed surface expression of the macrophage mannose receptor 2 (CD206) on bovine 244 
MoDCs (data not shown). Furthermore we could demonstrate that mannose blocked nearly 245 
70% of soluble OVA uptake (Fig. 3I), which is in accordance with a previous study using murine 246 
DCs [24]. Amantidine, an inhibitor of clathrin-mediated endocytosis, inhibited >80% uptake 247 
of all particles and soluble OVA. Poly-inosine, a scavenger receptor inhibitor, had no 248 
discernable effect.  249 
Next we looked at the effects of chitosan coatings to enhance PLGA nanoparticle 250 
uptake by MoDC (Fig. 4). Coatings were confirmed by assessing changes to the surface charge 251 
of particles (Fig. 4A). The positively charged oligomers reduced the negative surface charge 252 
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of particles in a manner that correlated with the size of the respective chitosan molecules. 253 
The chitosan salts had the expected converse effects due to the slight negative charge 254 
bestowed by the carboxylic acid groups on carboxy methyl chitosan and the positive charge 255 
from chitosan HCl.  Coating of nanoparticles with chitosan impaired particle uptake especially 256 
when chitosan salts were used (Fig. 4B). The oligomer coated particles were taken up equally 257 
well regardless of molecular weight but still less efficiently than the non-coated particles. We 258 
could not rule out the possibility that this was due to the formation of larger particles or 259 
aggregates as the sample become extremely poly disperse after chitosan coating. Adherence 260 
of chitosan-coated particles to MoDC at 4oC was comparable to non-coated particles (data 261 
not shown) suggesting an impairment in active uptake.  However, in contrast to the results 262 
obtained with MAN- and OVA-coated particles, the co-incubation with soluble mannose 263 
reduced uptake of the oligomer chitosan coated particles by between 30-50%; this was not 264 
the case with chitosan salts (Fig. 4C).  265 
 266 
3.3. Monoclonal antibody coating of PLGA nanoparticles 267 
Finally we assessed whether conjugation of anti-bovine DEC-205 mAb to the surface of PLGA 268 
nanoparticles could specifically target this receptor on a bovine DC population. Staining of 269 
mAb-coated particles with a fluorochrome-conjugated secondary antibody confirmed coating 270 
of the majority of particles (Fig. 5A).  To test the selective uptake of these particles, a novel 271 
uptake assay was established involving a mixed culture of two DC populations: DEC-205- 272 
MoDC (pre-labelled with CFSE to aid discrimination) competing for particles with DEC-205+ 273 
ALDC (Fig. 5B). Compared to ALDC, there were far more MoDCs associated with particles 274 
regardless of the coating (Fig. 5C). Coating with the isotype control or DEC-205 mAb increased 275 
the proportion of MoDC that had taken up particles by 21% and 17%, respectively. In the case 276 
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of the ALDC, the percentage of cells that had taken up particles was significantly enhanced by 277 
the addition of DEC-205 mAb but not with particles coated with the isotype control mAb (Fig. 278 
5C). When assessing particle uptake on a per cell basis, there was a significant increase using 279 
DEC-205 mAb coated particles compared to control mAb-coated particles by the ALDC, but 280 
not MoDC population (Fig. 5D). Co-coating with both chitosan and mAb reduced overall 281 
uptake by almost five-fold nonetheless the trend for DEC-205 mAb to increase uptake in ALDC 282 
was conserved (Fig. 5E).   283 
 284 
4. Discussion 285 
PLGA nanoparticles offer a malleable system for the targeted delivery of antigens and 286 
adjuvants. Enhancing the uptake of nanoparticles by DCs in vitro is an important step prior to 287 
in vivo evaluation. This study firstly confirmed the uptake of PLGA particles by different bovine 288 
DC populations demonstrating their versatility for veterinary applications. This study further 289 
evaluated specific uptake utilising two of the most popular means of DC targeting: natural 290 
ligands and mAb. No enhancement of DC uptake using mannosylated particles was observed, 291 
which could be due to the relatively neutral charge of the mannosylated particles produced, 292 
since previous studies have found that mannosylation bestows a more negative charge and 293 
that may facilitate enhanced uptake [7].  Similar to results obtained with murine DC [24], we 294 
found that soluble OVA uptake by bovine MoDC was inhibited by mannose. We therefore 295 
coated particles in OVA with the aim of replicating this effect. This could not be achieved, 296 
despite the particles retaining a negative charge, and the particle uptake resembled that of 297 
non-coated particles. This is consistent with an uptake model in which the particulate nature 298 
and factors such as charge and size may play a more important role than the surface ligands. 299 
In support of this concept it has been reported that mannosylation increases uptake by cells 300 
14 
 
lacking a defined mannose receptor [25]. In contrast to mannosylation, chitosan oligomer 301 
coated particle uptake was partially inhibited by mannose as had previously been described 302 
using non-particulate oligo-chitosan that specifically bound the macrophage mannose 303 
receptor (CD206) on macrophages [26, 27]. The uptake inhibition of chitosan, as opposed to 304 
MAN-coated particles, may be due to the number of ligands available, where MAN was 305 
dependent on the reaction between single residues on each of the particle’s polymers, 306 
chitosan could completely coat the surface due to electrostatic interactions. Chitosan-coated 307 
particles were taken up by the DCs to a lesser extent compared with non-coated particles.  308 
There are reports stating that chitosan coating enhances uptake although these particles 309 
were tested on tumour cell lines which may lack the necessary endocytic pathways to take up 310 
PLGA particles to the same extent. Moreover, chitosan is more adherent possibly co-localizing 311 
the particle to the cell surface prolonging the window of uptake [28].  312 
Finally we used mAb to target particles to the DEC-205 receptor which is expressed on 313 
defined bovine DC populations in vivo. Two DC populations, MoDCs and ALDC, were employed 314 
in a competitive uptake study. A similar model has recently been used to assess mannosylated 315 
particle uptake [29]. As only ALDCs express DEC-205 we could evaluate the ability of mAb to 316 
target particles to these cells. MoDCs were far superior to ALDC at particle uptake; this is likely 317 
due to ALDC representing a maturing population with reduced endocytic capacity. However, 318 
mAb targeting specifically increased the number of ALDC taking up particles. Interestingly, 319 
coating with irrelevant isotype mAb significantly enhanced uptake of particles by MoDC. This 320 
was not due to a decrease in particle surface charge (data not shown) resulting in less 321 
electrostatic repulsion and may rather reflect binding of mAb coated particles to Fc receptors. 322 
The enhancement of uptake when particles were coated with mAb has previously been 323 
described using microparticles and this effect was not observed when coating with BSA [30]. 324 
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This suggests it is a property of immunoglobulin, and not protein in general, which is 325 
responsible for improved uptake and is consistent with our finding that OVA coating did not 326 
augment uptake. Compared to MoDCs, DEC-205 mAb coating increased the amount of 327 
particles taken up by ALDC on a per cell basis. Whilst the addition of chitosan reduced uptake, 328 
specific uptake of DEC-205 mAb coated particles by ALDCs was still observed. This may be due 329 
to the chitosan restricting non-specific uptake as previously observed and thus limiting MoDC 330 
uptake. However, the use of chitosan in this role complicates the picture as the earlier 331 
experiments had suggested that it could bind to mannose receptors on MoDC. Overall our 332 
data supports earlier studies showing that the increased affinity of antibodies specific for 333 
target cells results in greater binding and uptake when compared to natural ligands [31].  334 
The establishment of the assay and model systems presented in this study provides a 335 
solid basis for the further screening and evaluation of DC receptor targeted nanocarriers 336 
which could be then be assessed in cattle, as a relevant large animal model for vaccine 337 
development. Whilst the enhanced targeting of mAb-coated particles to CD205+ DCs is 338 
encouraging the predominant uptake by MoDC highlights the challenge faced when delivering 339 
particles to the in vivo milieu of phagocytes and cellular processes.  Further work should 340 
evaluate the inclusion of a ‘stealth’ layer such as polyethylene glycol to make the particles 341 
more resistant to non-specific uptake and to further explore the effect of physical parameters 342 
on the uptake route of particles in both in vitro and in vivo models.  343 
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 452 
FIGURE LEGENDS 453 
 454 
Fig. 1. Assessment of PLGA nanoparticle uptake by bovine MoDCs. PLGA nanoparticles 455 
loaded with Alexa Fluor-488-conujugated OVA, as assessed by scanning electron microscopy 456 
(A), were incubated with bovine MoDCs for 1 hr at 37oC or 4oC. Flow cytometry was used to 457 
quantify the association of MoDCs with particles at 37oC (blue) and 4oC (red) (B). Data are 458 
representative of three independent experiments. 459 
 460 
Fig. 2. Assessment of the coating of PLGA nanoparticles with sugar or protein motifs. PLGA 461 
nanoparticles were coated with mannan (MAN) and OVA using the carbodiimide cross-linker 462 
EDC (A). Surface bound MAN (B) and OVA (C) were quantified by determining unreacted 463 
ligands in the wash supernatants of particles using a resorcinol assay and absorbance at 464 
280nm, respectively (data represent a single experiment). To assess MAN- and OVA-coating 465 
using flow cytometry, non-coated particles (D, F) or MAN- (E) and OVA-coated (G) particles 466 
were incubated with ConA-FITC or mouse anti-OVA mAb followed by anti-mouse IgG1-APC 467 
secondary antibody to detect mannose residues and OVA, respectively. Data representative 468 
of one of three experiments are shown. The effects of MAN and OVA coating on the surface 469 
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charge (H) and size of particles (I) were also assessed by dynamic light scattering, data 470 
represents readings in triplicate.  471 
 472 
Fig. 3. Assessment of the mechanisms of MoDC uptake of PLGA nanoparticles coated with 473 
sugar or protein motifs. MoDC uptake of Alexa Fluor-488-conujugated OVA loaded PLGA 474 
nanoparticles which were either non-coated (NT) or coated with MAN or OVA was assessed 475 
in comparison to soluble Alexa Fluor-488-conujugated OVA (sOVA) by flow cytometry. Uptake 476 
of particles was calculated by subtraction of the mean fluorescence intensity (MFI) of cells 477 
incubated at 4oC from the values obtained at 37oC (A). To assess the mechanism of uptake, 478 
MoDCs were pre-incubated for 30 min at 37oC with a panel of inhibitors; poly-inosine (pI), 479 
mannan (MAN), or amantidine (Am). Cells were then exposed to Alexa Fluor-488-conujugated 480 
OVA loaded PLGA nanoparticles which were either non-coated (F) or coated with MAN (G) or 481 
OVA (H), or to soluble Alexa Fluor-488-conujugated OVA (I), and after 1 hr incubation uptake 482 
was assessed using flow cytometry. Representative dots plots are shown for uptake of 483 
particles in the uninhibited (B), Am inhibited (C), MAN inhibited (D) and pI inhibited (E) 484 
conditions. The percentage inhibition of particle uptake was calculated from the difference in 485 
mean fluorescence intensity (MFI) between the uninhibited and the inhibited conditions (F-486 
I). Data presented are the mean of three experiments and error bars represent SEM. 487 
 488 
Fig. 4. The uptake of chitosan coated PLGA nanoparticles by MoDC and its inhibition by co-489 
incubation with soluble mannan. Alexa Fluor-488-conjugated OVA loaded PLGA particles 490 
were either left non-coated or incubated with chitosan salts; carboxymethyl chitosan 491 
(mChitosan) or chitosan HCl (HCl). Alternatively oligomers of chitosan were used and are 492 
represented by their respective molecular weights. Coating was confirmed by assessing the 493 
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change in surface charge by dynamic light scattering and error bars represent SD of 3 readings 494 
(A). To assess uptake, MoDCs were either incubated with particles for 1 hr incubation at 4 or 495 
37oC, and the fluorescence of cells was assessed by flow cytometry. Uptake of particles was 496 
calculated by subtraction of the mean fluorescence intensity (MFI) of cells incubated at 4oC 497 
from the values obtained at 37oC (B). Alternately, MoDC were pre-incubated with MAN for 1 498 
hr prior to being pulsed with particles and the percentage inhibition calculated (C). The mean 499 
of three experiments is shown with error bars representing SEM.  500 
 501 
Fig. 5. Assessment of the effect of anti-DEC-205 mAb coating of PLGA nanoparticles to target 502 
a specific DC population. PLGA nanoparticle coating with isotype control and anti-DEC-205 503 
mAbs was assessed using flow cytometry following staining with FITC conjugated anti-mouse 504 
IgG secondary antibody (A). Bovine ALDCs and MoDC were stained with a DEC-205 (blue) or 505 
irrelevant isotype control (red) mAb and analyzed by flow cytometry to confirm that a 506 
proportion of ALDC express DEC-205 whereas MoDC do not (B). Co-cultures of ALDC and 507 
MoDC were pulsed with OVA-Alexa Fluor 647 loaded PLGA nanoparticles, which were either 508 
non-coated (NT), or coated with an irrelevant isotype control mAb (isotype) or with anti-DEC-509 
205 mAb (DEC-205). The proportion of each DC type that had taken up particles was assessed 510 
by flow cytometry (C). The relative quantity of nanoparticles taken up by cells of each type 511 
was determined by the mean fluorescence intensity (MFI) measurements. To determine the 512 
effect of anti-DEC-205 mAb coating, the fluorescence of cells pulsed with anti-DEC-205 mAb 513 
coated particles were expressed as a fold increase in uptake over those pulsed with isotype 514 
control mAb coated particles. Uptake was compared with PLGA particles coated with mAb 515 
alone (D) or coated with 3-5 kDa oligo chitosan and mAb (E). The mean of three experiments 516 
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is shown, error bars represent SEM and statistical analysis was performed using a 2-way 517 
ANOVA (B) or t-test (C, D) **p<0.01 ***p<0.001. 518 
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